Status epilepticus

CONTINUUM Lifelong Learning in Neurology

Volumn 13, Issue 4 EPILEPSY, 2007, Pages 121-151

  Hirsch, Lawrence J ^a   Arif, Hiba ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BENZODIAZEPINE; CEFTRIAXONE; DIAZEPAM; ETIRACETAM; FOSPHENYTOIN SODIUM; GABAPENTIN; LORAZEPAM; MIDAZOLAM; OXCARBAZEPINE; PENTOBARBITAL; PHENYTOIN; PROPOFOL; TOPIRAMATE; VALPROIC ACID; WARFARIN; ZONISAMIDE;

ADULT; AGED; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EMERGENCY WARD; EPILEPTIC STATE; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LABORATORY TEST; LUMBAR PUNCTURE; MALE; MENTAL HEALTH; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; REVIEW; RISK FACTOR; TONIC CLONIC SEIZURE;

EID: 34548394074     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000284538.29811.da     Document Type: Review

References (64)

1. ▶ Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001;345(9):631-637. This randomized double-blinded study confirmed that benzodiazepines can be used safely in out-of-hospital settings (safer than placebo) and that IV lorazepam was superior to diazepam and placebo.
2. ▶ Baysun S, Aydin OF, Atmaca E, Gurer YK. A comparison of buccal midazolam and rectal diazepam for the acute treatment of seizures. Clin Pediatr (Phila) 2005;44(9):771-776. A comparative study showing that buccal midazolam is safe and as effective as rectal diazepam for emergency treatment of seizures.
3. ▶ Chin RF, Neville BG, Peckham C, et al. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet 2006;368(9531):222-229. Large population-based study reporting a higher incidence of convulsive SE in childhood with a range of causes, and a lower risk of death compared to adults.
4. ▶ Chong DJ, Hirsch LJ. Which EEG patterns warrant treatment in the critically ill? Reviewing the evidence for treatment of periodic epileptiform discharges and related patterns. J Clin Neurophysiol 2005;22(2):79-91. Comprehensive review of issues related to EEG patterns and nonconvulsive seizure diagnosis and management.
5. ▶ Claassen J, Hirsch LJ, Emerson RG, et al. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001;57(6):1036-1042. A large series of midazolam use for the treatment of refractory status epilepticus (SE) in 33 patients. Although effective, there was a high rate of breakthrough and withdrawal seizures, almost all nonconvulsive, on continuous EEG monitoring.
6. ▶ Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002a;43(2):146-153. This comprehensive review suggests that treatment with pentobarbital, or perhaps any continuous IV antiepileptic drug (AED) infusion to attain EEG background suppression, may be a more effective treatment for refractory SE, but at the expense of greater side effects and no difference in ultimate outcome.
7. ▶ Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. J Neurol Sci. 2003;211(1-2):37-41. This survey found lorazepam to be the most commonly used treatment for SE, followed by phenytoin or fosphenytoin as first-line and second-line therapies for generalized convulsive SE.
8. ▶ Claassen J, Lokin JK, Fitzsimmons BF, et al. Predictors of functional disability and mortality after status epilepticus. Neurology 2002b;58(1):139-142. This retrospective study found older age, the presence of acute symptomatic seizures, and longer hospital stay to be independent predictors of a worse prognosis in SE.
9. ▶ Claassen J, Mayer SA, Kowalski RG, et al. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology 2004;62(10):1743-1748. This study of 570 patients illustrates the importance of continuous EEG monitoring in detecting nonconvulsive seizures and nonconvulsive status epilepticus (NCSE) in the ICU setting, especially in comatose patients. More than 90% of the seizures that were recorded were nonconvulsive and would have been missed without EEG monitoring.
10. ▶ DeGiorgio CM, Heck CN, Rabinowicz AL, et al. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology 1999;52(4):746-749. Preliminary study suggesting an important role for neuron-specific enolase as a neuronal injury marker.
11. ▶ DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46(4):1029-1035. A prospective, population-based study documenting the incidence and mortality associated with SE.
12. ▶ DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol 1995;12(4):316-325. A cross-sectional study reporting incidence, morbidity, and mortality of SE in both hospital and community settings.
13. ▶ DeLorenzo RJ, Towne AR, Pellock JM, Ko D. Status epilepticus in children, adults, and the elderly. Epilepsia 1992;33(suppl 4):S15-S25.
14. ▶ DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998;39(8):833-840. A prospective study of 164 patients with convulsive SE; continuous EEG monitoring after controlling the convulsions revealed that 48% still had nonconvulsive seizures.
15. ▶ Eriksson K, Kalviainen R. Pharmacologic management of convulsive status epilepticus in childhood. Expert Rev Neurother 2005;5(6):777-783. This review outlines the treatment for convulsive SE in children.
16. ▶ Fudio S, Carcas A, Pinana E, Ortega R. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. J Clin Pharm Ther 2006;31(4):393-396. Report of a patient in whom seizures were induced secondary to a decrease in valproate serum levels due to an interaction with meropenem.
17. ▶ Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology 1998;50(1):301-303. Report of two pediatric cases of propofol infusion syndrome.
18. ▶ Hesdorffer DC, Logroscino G, Cascino G, et al. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 1998;50(3):735-741. Large study reporting incidence of SE in Rochester, Minnesota.
19. ▶ Husain AM, Horn GJ, Jacobson MP. Non-convulsive status epilepticus: usefulness of clinical features in selecting patients for urgent EEG. J Neurol Neurosurg Psychiatry 2003;74(2):189-191. A prospective study that found that a diagnosis of NCSE is particularly likely if a patient has remote risk factors for seizures, a severely impaired mental state, or ocular movement abnormalities.
20. ▶ Husain AM, Mebust KA, Radtke RA. Generalized periodic epileptiform discharges: etiologies, relationship to status epilepticus, and prognosis. J Clin Neurophysiol 1999;16(1):51-58. A retrospective study, reporting that clinical and generalized periodic epileptiform discharge (GPED) features differ between patients in SE and those not in SE, and those with good and poor prognoses, but a high intragroup variability precludes any generalizations regarding etiology, treatment, or prognosis in individual patients with GPEDs on EEG.
21. ▶ Jaitly R, Sgro JA, Towne AR, et al. Prognostic value of EEG monitoring after status epilepticus: a prospective adult study. J Clin Neurophysiol 1997; 14(4):326-334. This study reported that certain EEG patterns (normalization of the EEG, after SE ictal discharges, burst suppression, and periodic lateralized epileptiform discharges) are useful predictors of outcome in SE in addition to etiology.
22. ▶ Jenssen S, Gracely EJ, Sperling MR. How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit. Epilepsia 2006;47(9):1499-1503. This comparative study reported durations of the most common seizure types (both clinical and electrographic seizures).
23. ▶ Jirsch J, Hirsch LJ. Nonconvulsive seizures: developing a rational approach to the diagnosis and management in the critically ill population [published online ahead of print June 22, 2007]. Clin Neurophysiol.
24. ▶ Jordan KG. Continuous EEG monitoring in the neuroscience intensive care unit and emergency department. J Clin Neurophysiol 1999;16(1):14-39. A review of the current and potential applications of continuous EEG.
25. ▶ Jordan KG, Hirsch LJ. In nonconvulsive status epilepticus (NCSE), treat to burst-suppression: pro and con. Epilepsia. 2006;47(suppl 1):41-45. This article, based on a debate at a national meeting, reviews the pros and cons of aggressive treatment of NCSE.
26. ▶ Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001;42(suppl 4):13-18. An article reviewing the evidence that levetiracetam may have antiepileptogenic properties.
27. ▶ Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia 1996;37(9):863-867. This study reported that relapse of (refractory) SE after treatment with barbiturates is a poor prognostic sign and suggests a role for prolonged use of phenobarbital during pentobarbital withdrawal to prevent relapse.
28. ▶ Lahat E, Goldman M, Barr J, et al. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ 2000;321(7253):83-86. This study showed that intranasal midazolam stopped seizures faster than IV diazepam (due to faster administration) and both were well tolerated; thus intranasal midazolam represents a treatment option for use at home.
29. ▶ Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia 2000;41(10):1342-1345.
30. ▶ Limdi NA, Shimpi AV, Faught E, et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005;64(2):353-355. A retrospective study that reported good efficacy (63%) and tolerability of IV valproate (mean dose 31.5 mg/kg) in patients with SE.
31. ▶ Litt B, Wityk RJ, Hertz SH, et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia 1998;39(11):1194-1202. A study of 24 critically ill elderly patients with NCSE, which reported no improvement in outcome with more aggressive treatment.
32. ▶ Logroscino G, Hesdorffer DC, Cascino G, et al. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia 2001;42(8):1031-1035. A study reporting recent trends in the incidence, mortality, and case fatality of epilepsy.
33. ▶ Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993;43(3 pt 1):483-488. The results of this retrospective study suggested that etiology may help predict the initial response to treatment as well as short-term outcome in patients with SE. Also, first-line medications control SE in 80% of patients when initiated within 30 minutes, but in only 40% if started after 2 hours of onset.
34. ▶ Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998; 338(14):970-976. A comprehensive review of the diagnosis and management of SE.
35. ▶ Lowenstein DH, Bleck T, MacDonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999;40(1):120-122. The authors propose a revision of the traditional definition of SE (seizure activity persisting for at least 30 minutes) to a cutoff of 10 minutes, since there is evidence that very few seizures last more than 5 minutes.
36. ▶ Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59(2):205-210. A retrospective study that reported an association of refractory SE with NCSE and focal motor seizures at the onset.
37. ▶ Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res 1998;814(1-2):179-185. In this study, animal data are presented, supporting the concept that pharmacologic therapeutic interventions are most effective when initiated early and that efficacy decreases significantly with increasing seizure duration.
38. ▶ McDonald R, McLean M. Anticonvulsant drugs: mechanisms of action. Adv Neurol 1986;44:713-736. Early review of cellular and molecular mechanisms of epilepsy and AEDs.
39. ▶ McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005;366(9481):205-210. A randomized trial of buccal midazolam versus rectal diazepam in children presenting to a hospital with acute seizures: buccal midazolam was more effective with equal tolerability.
40. ▶ Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006;67(2):340-342. A pilot study of 68 patients with SE, documenting superior efficacy of IV valproate (66%) compared with IV phenytoin (42%) as first-line treatment; tolerability between the two groups did not differ.
41. ▶ Naritoku DK, Sinha S. Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology 2000;54(6):1366-1368.
42. ▶ Nei M, Lee JM, Shanker VL, Sperling MR. The EEG and prognosis in status epilepticus. Epilepsia 1999;40(2):157-163. This study found an association between occurrence of periodic discharges on EEG and worse outcome.
43. ▶ Niebauer M, Gruenthal M. Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res 1999;837(1-2):263-269. Preliminary data suggesting neuroprotective properties of topiramate.
44. ▶ Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus - experience in 102 adult patients. Seizure 2005;14(3):164-169. This study demonstrates the utility of valproate as a treatment for acute seizures.
45. ▶ Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006;47(7):1128-1135. This study demonstrated safety and tolerability of IV levetiracetam in normal volunteers at higher and faster rates of up to 2500 mg in 5 minutes or 4000 mg over 15 minutes.
46. ▶ Robakis TK, Hirsch LJ. Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care 2006;4(1):35-46. The authors and multiple experts discuss the case of a 30-year-old woman with severe, prolonged refractory SE requiring more than 6 months of iatrogenic coma.
47. ▶ Rossetti AO, Bromfield EB. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol 2005;54(1):34-38. This study suggests a role for oral levetiracetam for treatment of SE.
48. ▶ Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 2006;77(5):611-615. This study identified older age and marked impairment of consciousness as predictor of mortality in SE.
49. ▶ Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005;62(11): 1698-1702. The results of this study suggested that outcome was independent of treatment aggressiveness, and the underlying cause of SE may be the main determinant of outcome.
50. ▶ Rossetti AO, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004;45(7):757-763. This is the first series to show that propofol, in this case combined with a benzodiazepine infusion, was effective and safe for the treatment of refractory SE.
51. ▶ Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999;353(9153):623-626. This study found that outpatient treatment with buccal midazolam was slightly more effective than rectal diazepam for seizures in children lasting more than 5 minutes (75% versus 59%, P=.16). It also illustrated the ease of use and social acceptability of buccal midazolam.
52. ▶ Shinnar S, Pellock JM, Moshe SL, et al. In whom does status epilepticus occur: age-related differences in children. Epilepsia 1997;38(8):907-914. Retrospective analysis of records of 394 children that reported an effect of age on the frequency and etiology of SE; acute symptomatic causes, including febrile seizures, were more common in children younger than 2 years (80% of cases), while cryptogenic and remote symptomatic causes were more common in older children (P<.001).
53. ▶ Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003;61(8):1066-1073. This study reported worse outcome in patients with an acute medical (systemic or neurologic) cause of NCSE (27% mortality) as compared with those without an acute medical cause (3%). Patients with severe mental status impairment also had a high mortality rate (39%).
54. ▶ Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000;55(5):722-724. This study reported good tolerability of IV valproate in 13 patients with SE and hypotension.
55. ▶ Tay SK, Hirsch LJ, Leary L, et al. Nonconvulsive status epilepticus in children: clinical and EEG characteristics. Epilepsia 2006;47(9):1504-1509. This study of 19 pediatric patients with NCSE reported that although most children with NCSE will have had acute seizures prior to onset of NCSE, in many cases these seizures are brief, isolated convulsions.
56. ▶ Towne AR, Garnett LK, Waterhouse EJ, et al. The use of topiramate in refractory status epilepticus. Neurology 2003;60(2):332-334. This study documents a potential role for topiramate (at dosages ranging from 300 mg/d to 1600 mg/d) as treatment for patients in refractory SE.
57. ▶ Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994;35(1):27-34. The first multivariate analysis of predictors of outcome in SE, this study identified anoxia and increasing age to be significantly correlated with higher mortality.
58. ▶ Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000;54(2):340-345. This study underscored the need to include EEG in the routine evaluation of comatose patients: NCSE was identified in 8% of all comatose patients who had no signs of seizure activity.
59. ▶ Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339(12):792-798. This is a very important large, randomized, double-blind, multicenter trial of four regimens: diazepam plus phenytoin, phenytoin alone, lorazepam alone, and phenobarbital alone. The study showed that lorazepam was the most effective first-line agent for treatment of SE, although this only reached significance when compared with phenytoin alone; no significant differences were found between other treatment arms.
60. ▶ van Gestel JP, Blusse van Oud-Alblas HJ, Malingre M, et al. Propofol and thiopental for refractory status epilepticus in children. Neurology 2005;65(4):591-592. This study reported that propofol, despite prior reports, was a safe and effective treatment of refractory SE in children. The authors suggest a trial of propofol before thiopental, which was associated with serious side effects in this study.
61. ▶ Vespa PM, Nuwer MR, Nenov V, et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg 1999;91(5):750-760. This study showed that seizures in patients with intracerebral hemorrhage are associated with increased midline shift independent of the size of hemorrhage.
62. ▶ Wheless JW, Vazquez BR, Kanner AM, et al. Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology 2004;63(8): 1507-1508.
63. ▶ White JR, Santos CS. Intravenous valproate associated with significant hypotension in the treatment of status epilepticus. J Child Neurol 1999;14(12):822-823.
64. ▶ Young GB, Jordan KG, Doig GS. An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: an investigation of variables associated with mortality. Neurology 1996;47(1):83-89. This analysis highlighted the risk factors, primarily seizure duration and delay to diagnosis, that are associated with high mortality in NCSE.